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Integrin-mediated cell adhesion cooperates with
growth factor receptors in the control of cell prolifera-
tion, cell survival, and cell migration. One mechanism to
explain these synergistic effects is the ability of inte-
grins to induce phosphorylation of growth factor recep-
tors, for instance the epidermal growth factor (EGF)
receptor. Here we define some aspects of the molecular
mechanisms regulating integrin-dependent EGF recep-
tor phosphorylation. We show that in the early phases of
cell adhesion integrins associate with EGF receptors on
the cell membrane in a macromolecular complex includ-
ing the adaptor protein p130Cas and the c-Src kinase,
the latter being required for adhesion-dependent assem-
bly of the macromolecular complex. We also show that
the integrin cytoplasmic tail, c-Src kinase, and the
p130Cas adaptor protein are required for phosphoryla-
tion of EGF receptor in response to integrin-mediated
adhesion. We show that integrins induce phosphoryla-
tion of EGF receptor on tyrosine residues 845, 1068,
1086, and 1173, but not on residue 1148, a major site of
phosphorylation in response to EGF. In addition we find
that integrin-mediated adhesion increases the amount
of EGF receptor expressed on the cell surface. Therefore
these data indicate that integrin-mediated adhesion in-
duces assembly of a macromolecular complex contain-
ing c-Src and p130Cas and leads to phosphorylation of
specific EGF receptor tyrosine residues.
Integrins are cell surface-adhesive receptors formed by  and
 subunits, which bind to extracellular matrix proteins. Inte-
grin-mediated adhesion stimulates multiple signaling path-
ways that modulate actin cytoskeleton organization, cell motil-
ity, cell growth, and the ability of cells to escape from apoptosis.
Integrin-dependent signaling includes Ca2 influx, cytoplasmic
alkalinization, potassium channel activation, tyrosine phos-
phorylation of cytoplasmic proteins, and activation of the mi-
togen-activated protein (MAP)1 kinases ERK-1 and ERK-2 (for
review, see Refs. 1–5). Although many integrin-dependent sig-
naling pathways have been described extensively, the molecu-
lar mechanisms by which integrins are able to trigger these
events are still poorly defined.
Integrins have been shown to interact with transducing mol-
ecules to promote intracellular signaling. Potential candidates
as transducing elements are tyrosine kinases of the Fak and
Src family. The amino-terminal domain of p125Fak (6, 7) binds
in vitro the cytoplasmic domain of the 1 and 3 integrin
subunits, whereas its carboxyl-terminal part binds the SH2
and SH3 domains of several proteins involved in focal adhesion
assembly and signal transduction (for review, see Ref. 8). After
activation by most integrins, p125Fak is phosphorylated on
tyrosine 397, which becomes a high affinity binding site for the
SH2 domain of c-Src (9). The Src kinase then phosphorylates
focal adhesion components, such as the cytoskeletal proteins
talin, paxillin, the adaptor p130Cas, and the p125Fak itself on
the tyrosine 925, leading to signaling functions. It has been
shown that phosphorylated p125Fak interacts with the adaptor
molecule Grb-2, leading to MAP kinase activation (10) through
a B-Raf-dependent pathway (11). In addition to p125Fak, some
1 and v integrins activate the Src family member Fyn and the
adaptor Shc. The assembly of this transduction complex in-
volves caveolin, a transmembrane protein that cooperates with
integrins to activate signaling pathways. After cell-matrix ad-
hesion, integrin-caveolin-Fyn complexes associate with tyro-
sine-phosphorylated Shc, which, in turn, interacts with the
Grb2Sos complex leading to activation of the Ras-MAP kinase
cascade (12). Integrins can also associate with proteins belong-
ing to the Tetraspan family (CD9, CD63, and CD81) to modu-
late intracellular signaling (13).
Integrin-dependent activation of the small GTPase Rac (for
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review, see Refs. 14 and 15) has also been proposed recently as
an additional mechanism to regulate adhesion-dependent
events, such as integrin activation of Jun NH2-terminal kinase
(16). Integrin regulation of Rac activation can occur through
the adaptor molecules p130Cas and Crk (16, 17), likely through
the involvement of a Rac-specific guanine nucleotide exchange
factor, such as Vav (18).
In addition to these molecules, growth factor receptors are
candidates to cooperate with integrins in assembling a trans-
duction machinery. Integrins have been shown to potentiate
signaling pathways in response to insulin, platelet-derived
growth factor, epidermal growth factor (EGF), fibroblast
growth factor, and vascular endothelial growth factor (19–29).
In particular, v3 integrin has been shown to synergize with
different growth factor receptors. v3 integrin occupancy by
its matrix ligand is required for full tyrosine phosphorylation of
insulin and platelet-derived growth factor  receptors and their
binding to several signaling molecules such as insulin receptor
substrate 1, phospholipase C, Ras GAP, the p85 subunit of
phosphatidylinositol 3-kinase and the tyrosine phosphatase
SHP2 (19, 22). In endothelial cells, moreover, v3 integrin
potentiates the activation of vascular endothelial growth factor
receptor and of p85 phosphatidylinositol 3-kinase by its ligand
(28).
Direct phosphorylation of growth factor receptors by inte-
grin-mediated adhesion represents a potential mechanism by
which integrins can enhance signaling pathways emanating
from growth factor receptors (30–33).
We have shown recently that in cells expressing more than
104 EGF receptors/cell, integrins induce EGF receptor tyrosine
phosphorylation in the absence of EGF receptor ligands, lead-
ing to Shc phosphorylation and MAP kinase activation (33). In
this work we show that integrins, c-Src, p130Cas, and EGF
receptor associate in a macromolecular complex on the cell
membrane and that integrin-dependent adhesion induces
phosphorylation of specific tyrosine residues of EGF receptor,
distinct from those obtained by soluble ligand EGF.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—The following antibodies to integrin sub-
units were used: monoclonal antibody (mAb) TS2/16 to the human 1
integrin subunit (purchased from ATCC), mAb L230 to the v integrin
subunit (from ATCC), mAb B212 to the 3 subunit, and the polyclonal
antibody to the 1 integrin cytoplasmic domain described previously
(34). All the monoclonal antibodies were affinity purified on protein
A-Sepharose as described (35), and the purity of the antibodies was
higher than 95%. Antibodies to the EGF receptor were: mAb HB-8509
and HB-8508 (purchased from ATCC), mAb to the activated form of
EGF receptor (purchased from Transduction Laboratories), and poly-
clonal Ab EGFR1 produced as described by Moro et al. (33). Polyclonal
antibodies to phosphorylated tyrosine 1068, 1086, 1148, and 1173 of the
EGF receptor were prepared from BIOSOURCE International. The
specificity of each antibody has been tested on extracts of EGF-treated
NIH3T3 cells expressing EGF receptor mutated on each specific tyro-
sine (data not shown). Polyclonal antibody to p125Fak Fak4 has been
described previously (33, 36). Rabbit anti-mouse IgGs were produced
and purified in our laboratory. mAb PY99 to phosphotyrosine, Crk, and
p130Cas were obtained from Transduction Laboratories. mAb to c-Src
was from Santa Cruz Biotechnology. Ab to phospho-p60Src (Tyr-416)
was a gift from Dr. L. Chen (Cell Signaling Technology).
Human recombinant EGF was from Sigma. 4-amino-5-(4-methylphe-
nyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine (PP1) and AG1478 were from
Calbiochem. Protein A-Sepharose, nitrocellulose, the ECL reagents,
and films were from Amersham Biosciences, Inc. Culture media, sera,
and LipofectAMINE reagent were from Invitrogen.
Cell Culture and Transfection—Human cell line ECV304 was pur-
chased from ATCC. GD251A and GD251TR cells have been described
previously (37). Mouse embryonic fibroblasts (MEFs) isolated from mu-
rine Fak/ and Fak/ embryos (38) were a kind gift from Dr. D. Ilic.
MEFs isolated from murine p130Cas/ embryos (39) were a kind gift
from Dr. T. Nakamoto. Cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. ECV304 cells grown
to 80% confluence in 100-mm tissue culture dishes were transiently
transfected with the pSGT Src K plasmid encoding a c-Src point
mutant kinase negative (gift from Dr. S. Courtneidge) by the Lipo-
fectAMINE reagent as described by the manufacturer. 20 h after trans-
fection the medium was changed to Dulbecco’s modified Eagle’s medium
containing 0.5% fetal calf serum, and cells were incubated for 24 h
before the adhesion assay.
Adhesion Assays—Cells grown to confluence were serum deprived in
Dulbecco’s modified Eagle’s medium for 24 h, detached with 10 mM
EDTA in phosphate-buffered saline, washed, and kept in suspension or
plated for 30 min on 10 g/ml fibronectin or 10 g/ml v integrin
antibody-coated dishes. In some experiments dishes were coated with
poly-L-lysine (PL), a nonspecific adhesive substrate, and postcoated
with antibodies to the v integrin subunit, a double coating that max-
imizes the rate of cell adhesion (33, 40). When indicated, human recom-
binant EGF, PP1, or AG1478 was added at the indicated dose. Cells
were then washed with phosphate-buffered saline containing 5 mM
EDTA, 10 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, and detergent
extracted in lysis buffer as described below. In the coimmunoprecipita-
tion experiments, at the end of adhesion cells were incubated for 30 min
at 4 °C in the presence of 30 g/ml monoclonal antibodies to integrin
subunits or to EGF receptor specifically to bind and immunoprecipitate
cell surface molecules, washed three times, and detergent extracted.
Cell Lysis, Immunoprecipitation, and Immunoblotting—Cells were
extracted with 1% Nonidet P-40 lysis buffer (1% Nonidet P-40, 150 mM
NaCl, 50 mM Tris-HCl, pH 8, 5 mM EDTA, 10 mM NaF, 10 mM Na4P2O7,
0.4 mM Na3VO4, 10 g/ml leupeptin, 4 g/ml pepstatin, and 0.1 unit/ml
aprotinin). Cell lysates were centrifuged at 13,000  g for 10 min, and
the supernatants were collected and assayed for protein concentration
using the Bio-Rad protein assay method. Proteins were run on SDS-
PAGE under reducing conditions. For immunoprecipitation experi-
ments, proteins were immunoprecipitated with the appropriate anti-
body for 1 h at 4 °C as described previously (33) in the presence of 50 l
of protein A-Sepharose beads. In the coimmunoprecipitation experi-
ments, integrins or EGF receptor were immunoprecipitated from the
cell surface. At the end of adhesion, intact cells were incubated with
anti-3, anti-v, or anti-EGF receptor mAbs to bind, respectively, v3
integrin or EGF receptor exposed on the cell surface and detergent
extracted. Protein A-Sepharose beads were then added to 3 mg of
protein cell extract to collect immunoprecipitates. After SDS-PAGE,
proteins were transferred to nitrocellulose, reacted with specific anti-
bodies, and then detected with peroxidase-conjugated secondary anti-
bodies and chemoluminescent ECL reagent. When appropriate, the
nitrocellulose membranes were stripped according to manufacturer’s
recommendations and reprobed. Densitometric analysis was performed
using the GS 250 molecular imager (Bio-Rad).
In Gel Tryptic Protein Digestion and Mass Spectrometric Analysis—
EGF receptor-containing bands were cut from the gel and destained
overnight with a solution of 50 mM ammonium bicarbonate, 40% etha-
nol. The protein was digested in gel with trypsin (Promega) according to
Hellman et al. (41) except that the bands had been washed three times
with acetonitrile before drying them in a speed vacuum concentrator.
For matrix-assisted laser desorption-ionization time-of-flight
(MALDI-TOF) mass spectrometry, aliquots of 0.5 l of the peptide
mixtures were applied to a target disc and allowed to air dry. Subse-
quently, 0.5 l of matrix solution (1% w/v -cyano-4-hydroxycinnamic
acid in 50% acetonitrile, 0.1% trifluoroacetic acid) was applied to the
dried sample and again allowed to dry. Spectra were obtained using a
Bruker Biflex III MALDI-TOF spectrometer (Bremen, Germany). For
interpretation of the protein fragments the MASCOT program available
at the Matrixscience web site (www.matrixscience.com) and the Pep-
tideMass program available at Expasy web site (www.expasy.ch/tools/
peptide-mass.html) were used.
Immunoelectron Microscopy—For immunoelectron microscopy, 10%
gelatin-embedded, 2.3 M sucrose-infused blocks of aldehyde-fixed
ECV304 cells were frozen in liquid nitrogen. Ultrathin cryosections
were obtained with a Reichert-Jung Ultracut E with FC4E cryoattach-
ment and collected on copper-formvar-carbon-coated grids. Single im-
munogold localization on ultrathin cryosections was performed as de-
scribed previously (42, 43). In particular, sections were immunostained
with anti-human EGF receptor mAb AB-5 (Oncogene Science) followed
by a rabbit anti-mouse bridging antibody (DAKO) and 15-nm protein
A-gold. Control sections have been incubated without first antibodies.
In all control sections no labeling was detected (not shown). Sections
were examined with a Zeiss EM 902 electron microscope.
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RESULTS
Integrins and EGF Receptor Associate in a Transducing Mac-
romolecular Complex—We have shown recently that adhesion
of human primary skin fibroblasts and ECV304 human cells to
immobilized matrix proteins or to antibodies to integrin sub-
units stimulates tyrosine phosphorylation of the EGF receptor
and association with 1 integrin (33). To investigate the molec-
ular nature of the complex between integrins and the EGF
receptor, we immunoprecipitated v3 integrins from ECV304
cells adherent to v ligand and performed Western blotting
experiments. Fig. 1A (top left panel) is an example of an inte-
grin-EGF receptor complex identified in ECV304 cells. Western
blotting with specific antibodies show that, in addition to the
EGF receptor, the adaptor molecules p130Cas, Crk, and c-Src
kinase, but not p125Fak, coimmunoprecipitate with v3 inte-
grin upon integrin-mediated adhesion (Fig. 1A, left panel). Sim-
ilar results were obtained by immunoprecipitating 1 integrin
in cells plated on fibronectin (Fig. 1B and data not shown).
Coimmunoprecipitation of the c-SrcCasCrk complex with in-
tegrins is strictly dependent on the presence of the EGF recep-
tor because these molecules organize in a macromolecular com-
plex only in ECV304 and EGF receptor-transfected NIH3T3
cells, expressing appreciably level of EGF receptor (20-40,000
molecules/cell), but not in wild type NIH3T3 that express
barely detectable level of EGF receptor (Fig. 1B).
Integrin-EGF Receptor Macromolecular Complex Is Tran-
siently Assembled—To investigate the kinetics of macromolec-
ular complex formation, ECV304 cells were plated on dishes
coated with v ligand, and assembly of the macromolecular
complex was analyzed at 5 and 15 min of adhesion. Integrins
were immunoprecipitated from the cell surface, and immuno-
precipitates were probed with antibodies to the EGF receptor,
p130Cas, and c-Src kinase. Western blotting experiments indi-
cate that these distinct components associate only when inte-
grin is engaged and not when cells are attached on PL (Fig. 2A)
or kept in suspension (not shown). The macromolecular com-
plex is clearly visible within 5 min of adhesion and becomes
undetectable at 15 min, indicating that the association between
these molecules is an early and transient event. The same
kinetics is also obtained by immunoprecipitating the EGF re-
ceptor and blotting with antibodies for each component (data
not shown). Previous results show that tyrosine phosphoryla-
tion of the EGF receptor is maximal within 30 min after plating
on matrix proteins and then decreases, reaching basal levels
within 4 h (33). In the experiments reported here, when cells
were plated on integrin ligands, the EGF receptor was already
phosphorylated at 5 min (Fig. 2B), showing that complex for-
mation occurs concomitantly to EGF receptor phosphorylation.
At 30 min of adhesion, when the complex is disassembled,
tyrosine phosphorylation of EGF receptors remains high, indi-
cating that at later times the kinetics of the two events are
distinct. Therefore these results indicate that in the early
phases of cells adhesion, integrin occupation leads to their
association with EGF receptors in a transient macromolecular
complex leading to sustained EGF receptor phosphorylation.
c-Src and EGF Receptor Kinases Are Both Required for As-
sociation of Integrin-EGF Receptor Macromolecular Com-
plex—We analyzed the activation state of the c-Src kinase
present in the integrin-EGF receptor macromolecular complex
using an antibody that recognizes phosphorylation of the crit-
ical tyrosine residue 416 in the Src kinase domain. c-Src is
phosphorylated on tyrosine 416 when ECV304 cells are plated
on integrin ligands, indicating that integrin-mediated adhesion
induces c-Src kinase autophosphorylation (Fig. 3A). In ECV304
cells plated on v ligand for 5 min, c-Src phosphorylated on
tyrosine 416 is detectable in integrin immunoprecipitates from
adherent cells but is absent in cells plated on PL (Fig. 3B,
bottom panel), indicating that c-Src is activated after adhesion
and that activated c-Src complexes with integrins and EGF
receptors. To test whether c-Src kinase activity is required for
assembly of the integrin-EGF receptor complex, coimmunopre-
cipitation experiments were performed in cells exposed to PP1,
a specific Src kinase inhibitor (Fig. 3A). After PP1 treatment,
EGF receptors, p130Cas, and c-Src were not detectable in the
immunoprecipitates of v3 integrin (Fig. 3B), suggesting that
inhibition of c-Src kinase activity prevents macromolecular
complex assembly. These results were confirmed by expression
of a kinase negative form of c-Src. In ECV304 cells expressing
the mutant Src kinase form the amount of EGF receptor in the
integrin immunoprecipitate is strongly reduced, as well as that
of p130Cas and c-Src (Fig. 3C). Similar results were obtained in
FIG. 1. Integrins and EGF receptors form a complex in re-
sponse to adhesion. A, ECV304 cells were detached from culture
dishes and plated for 5 min on dishes coated with mAb L230 to the v
integrin subunit. mAb B212 to the 3 subunit was then added to the
cells, which were incubated further for 30 min at 4 °C before detergent
extraction. Cells extracts were immunoprecipitated by the addition of
protein A-Sepharose (IP anti v3) or run as control on 6% SDS-PAGE
and blotted. Immunoblotting was performed with antibodies to EGF
receptor (EGFR), p130Cas, p125Fak, c-Src, and Crk. B, NIH3T3 and
NIH3T3 cells transfected with human EGF receptor (EGFR) were
plated on fibronectin-coated dishes for 5 min, and cell extracts were
immunoprecipitated with polyclonal antibodies to 1 integrin. Materi-
als coimmunoprecipitated with 1 integrin were run on gel and blotted,
respectively, with the antibodies to EGF receptor, p130Cas, and the 1
integrin subunit. The data reported here are representative of 10 dis-
tinct experiments.
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c-Src/ fibroblasts (not shown). Therefore these data indicate
that c-Src is needed for the assembly of the integrin-EGF
receptor complex.
We also evaluated the role of EGF receptor kinase in modu-
lating EGF receptor association with integrins by using tyr-
phostin AG1478, a specific inhibitor of EGF receptor kinase, in
FIG. 2. Kinetics of macromolecular complex association. ECV304 cells were plated for different times on dishes coated with PL and
postcoated with mAb L230 to the v integrin subunit. A, mAb B212 to the 3 subunit was added to the cells, which were incubated further for 30
min at 4 °C before detergent extraction. Cell extracts were immunoprecipitated by the addition of protein A-Sepharose (IP anti v3), run on 6%
SDS-PAGE, and immunoblotted with antibodies to EGF receptor (EGFR), p130Cas, and c-Src, as shown in Fig. 1. B, cells were detergent extracted
at the indicated times, and extracts were immunoprecipitated by antibodies to EGF receptor. The immunoprecipitates were blotted with antibody
PY99 to phosphotyrosine (upper panel) and reblotted with polyclonal antibodies to EGF receptor (lower panel). The data reported here are
representative of four distinct experiments.
FIG. 3. Assembly of integrin-EGF receptor macromolecular complex is dependent on c-Src and EGF receptor kinase activity. A,
ECV304 cells were detached from culture dishes and plated for 30 min on dishes coated with mAb L230 to the v integrin subunit in the presence
or absence of 5 M c-Src kinase inhibitor PP1. Cells were detergent extracted, and equal amounts of cell extracts were run on 10% SDS-PAGE and
immunoblotted with antibodies to phosphorylated tyrosine 416 of c-Src (pSrcY416) (upper panel) or the c-Src protein (lower panel). B, ECV304 cells
were plated for 5 min on dishes coated with PL and postcoated with mAb L230 to v integrin subunit in the presence or absence of 5 M Src inhibitor
PP1. Cell surface v3 was bound as described in Figs. 1 and 2 and immunoprecipitated by the addition of protein A-Sepharose (IP anti v3). Cell
extracts were run as a control. Immunoblotting was performed with antibodies to EGF receptor (EGFR), p130Cas, c-Src, and phosphorylated
tyrosine 416 of c-Src. C, ECV304 cells were transiently transfected for 40 h with control plasmid () or with pSGT Src K (), detached, plated
on v antibodies for 5 min on dishes coated with PL, and postcoated with mAb L230 to v integrin (v), and processed as in A. Immunoprecipitates
were blotted with antibodies to EGF receptor (top panel), p130Cas (middle panel), and c-Src (bottom panel). D, ECV304 cells were plated for 5 min
on dishes coated with PL and postcoated with mAb L230 to the v integrin subunit in the presence or absence of 250 nM tyrphostin AG1478 and
processed as in A. Cells extracts were immunoprecipitated by the addition of protein A-Sepharose (IP anti v3) or run as a control. Immunoblotting
was performed with antibodies to EGF receptor, p130Cas, and c-Src. The data reported here are representative of three distinct experiments.
Mechanisms of Integrin-dependent EGF Receptor Phosphorylation9408
the coimmunoprecipitation experiments. As shown in Fig. 3D,
in the presence of tyrphostin AG1478, EGF receptors and
p130Cas are not detectable in the integrin immunoprecipitate,
whereas c-Src is still present, even if reduced, indicating that
EGF receptor kinase activity is necessary for its ability to
associate with integrins but is not required for association
between integrins and c-Src.
c-Src but Not p125Fak Kinase Is Required for Integrin-me-
diated Tyrosine Phosphorylation of EGF Receptor—The data
shown above indicate that c-Src kinase is required to trigger
integrin/EGF receptor association. We then tested whether
c-Src kinase is also necessary for integrin-dependent EGF re-
ceptor phosphorylation. When cells are exposed to the Src
kinase inhibitor PP1, tyrosine phosphorylation of EGF recep-
tors induced by integrin-mediated adhesion is strongly reduced
(Fig. 4A). Similarly, expression of a kinase negative form of
c-Src strongly affects integrin-dependent tyrosine phosphoryl-
ation of EGF receptor but only slightly modifies tyrosine phos-
phorylation in response to EGF (Fig. 4, B and C). Similar
results were obtained using 10 or 50 ng/ml EGF (data not
shown). This result indicates that c-Src kinase has a primary
role in integrin-dependent EGF receptor tyrosine phos-
phorylation.
It is well established that p125Fak is regulated by integrin-
mediated adhesion and is a good substrate for Src kinase (for
review, see Refs. 3 and 8). The involvement of p125Fak kinase
in integrin-dependent EGF receptor activation has been tested
by comparing p125Fak/ MEFs with wild type cells (38).
p125Fak/ cells plated on fibronectin show the same extent
of EGF receptor phosphorylation as the wild type MEFs (Fig.
4D), indicating that p125Fak is not involved in EGF receptor
phosphorylation. In addition, expression of a kinase-defective
(CD2FakK454R) and of a tyrosine autophosphorylation mutant
(CD2FakY397F) of p125Fak in ECV304 cells does not affect
EGF receptor tyrosine phosphorylation after adhesion (data
not shown), further supporting the conclusion that p125Fak is
not required for integrin-mediated signaling leading to EGF
receptor phosphorylation.
p130Cas and the Integrin Cytoplasmic Domain Are Required
for Integrin-dependent Phosphorylation of EGF Receptors—The
experiments reported above underline that EGF receptors
transiently associate with integrins in combination with other
molecules known to be involved in integrin-dependent signal
transduction, such as the adaptor protein p130Cas (44). To
dissect the molecular mechanisms of integrin-dependent EGF
receptor phosphorylation, we tested whether the 1 integrin
cytoplasmic domain and p130Cas are relevant to this process.
The contribution of the 1 cytoplasmic domain was analyzed by
using GD25 cells derived from 1 integrin-null mice (45). These
cells have been stably transfected with 1 integrin (1A) or with
1TR integrin mutant, lacking all of the cytoplasmic domain
(37). Cells were plated on dishes coated with anti-1 integrin
mAb TS2/16 in order to trigger only 1 integrin-dependent
signals. Upon adhesion to 1 ligand, GD251A cells show in-
duction of EGF receptor phosphorylation, but GD251TR cells
do not (Fig. 5A). Therefore these data indicate that the 1
cytoplasmic domain is required to trigger EGF receptor phos-
phorylation. Interestingly, in the same experimental condi-
tions, EGF receptors are phosphorylated by EGF in both
GD251A and GD251TR cells, indicating that EGF-induced
FIG. 4. c-Src kinase activity is required to trigger EGF receptor phosphorylation in response to adhesion. A, ECV304 cells were
detached from culture dishes and plated for 30 min on dishes coated with mAb L230 to the v integrin subunit in the presence or absence of 5 M
c-Src kinase inhibitor PP1. EGF receptor was immunoprecipitated with mAb 8509 from ECV304 cells adherent to v antibodies, run on 6%
SDS-PAGE, and blotted with antibodies to phosphotyrosine (upper panel) or to EGF receptor (lower panel). B, ECV304 cells were transiently
transfected with control plasmid () or with pSGT Src K (), treated with 50 ng/ml EGF or detached and plated on v antibodies for 30 min (v).
Immunoprecipitated EGF receptor was blotted with antibodies to phosphotyrosine (top panel) or to EGF receptor (middle panel). Cell extracts were
blotted with antibodies to the c-Src kinase protein (bottom panel). C, densitometric analysis of the experiment reported in B: control plasmid (Co),
pSGTSrc K (Src k). Levels of EGF receptor phosphorylation are reported in arbitrary units. D, MEFs derived from Fak/ and Fak/
embryos were detached from culture dishes and plated for 30 min on fibronectin-coated dishes. Immunoprecipitated EGF receptor (EGFR) was
immunoblotted with antibodies to phosphotyrosine (upper left panel) or to EGF receptor (lower left panel); cell extracts were visualized for Fak
expression with antibodies to p125Fak (right panel). The data reported here are representative of four distinct experiments.
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phosphorylation is independent of the presence of the 1 inte-
grin cytoplasmic domain and distinct from phosphorylation
obtained by integrin-mediated adhesion.
In addition, using an antibody that recognizes phosphoryla-
tion of the tyrosine residue 416 in the Src kinase domain, we
show that c-Src is phosphorylated on this tyrosine in both
GD251A and GD251TR cells plated on 1 integrin ligand,
indicating that the lack of EGF receptor activation in
GD251TR does not depend on defective c-Src activation (Fig.
5B). p130Cas has been described as a major c-Src-dependent
phosphorylated protein upon cell/matrix interaction (44, 46–
48). The extent of p130Cas tyrosine phosphorylation observed
in GD251TR cells plated on 1 ligand is strongly reduced
compared with that obtained in GD251A cells, suggesting
that the 1 integrin cytoplasmic domain is involved in adhesion-
dependent p130Cas tyrosine phosphorylation (Fig. 5C) and
that, in the absence of the 1 cytoplasmic domain, c-Src acti-
vation is not sufficient to trigger massive adhesion-dependent
p130Cas phosphorylation.
Because p130Cas is a component of the integrin-EGF recep-
tor complex, we investigated the role of this protein in EGF
receptor phosphorylation using p130Cas-deficient cells. Wild
type and p130Cas/MEFs were plated on fibronectin or kept
in suspension, and EGF receptors were immunoprecipitated
within 30 min of adhesion. p130Cas/ fibroblasts were un-
able to trigger EGF receptor phosphorylation upon fibronectin
adhesion (Fig. 5D), showing that the presence of the p130Cas
molecule is required to trigger integrin-dependent EGF recep-
tor phosphorylation.
Integrin-mediated Adhesion Leads to Phosphorylation of
Specific Residues on EGF Receptors—We have shown previ-
ously that integrin-dependent EGF receptor phosphorylation is
quantitatively lower than that obtained in response to EGF
(33). To define which tyrosine residues are phosphorylated by
cell-matrix adhesion we used MALDI-TOF mass spectrometry
and antibodies to specific EGF receptor tyrosine residues. To
analyze tyrosine residues phosphorylated in integrin-mediated
adhesion, MALDI-TOF mass spectrometry analysis was per-
formed on EGF receptors purified by affinity chromatography
from cells plated on v ligand or kept in suspension. As shown
in Table I tryptic peptides containing tyrosine residues 845 and
1068 are found phosphorylated in cells adherent to integrin
ligand and not phosphorylated in cells kept in suspension,
indicating that these two residues are targets of integrin-me-
diated adhesion. Interestingly, peptides containing tyrosine
1148 are not phosphorylated in response to integrin-mediated
adhesion, but they are phosphorylated in response to EGF
(data not shown), because tyrosine 1148 is a major EGF-de-
pendent autophosphorylation site (49, 50).
These data were confirmed by using antibodies to specific
tyrosine residues of EGF receptor. As shown in Fig. 6, tyrosine
1068 is phosphorylated strongly by cell-matrix adhesion (top
panel), whereas tyrosine 1148 is not (third panel from top). As
expected, both tyrosines are highly phosphorylated by EGF
FIG. 5. EGF receptor phosphorylation is dependent on 1 integrin cytoplasmic domain and p130Cas. A, GD251A and GD251TR
cells were plated for 30 min on dishes coated with mAb TS2/16 to the 1 integrin subunit in the presence or absence of 50 ng/ml EGF or kept in
suspension (S). Cell extracts were immunoprecipitated by antibodies to EGF receptor (EGFR) or p130Cas, and the immunoprecipitates (IP) were
blotted with antibody PY99 to phosphotyrosine (upper panels) and reblotted with polyclonal antibodies to the EGF receptor (lower panels). B, cell
extracts of GD251A and GD251TR cells treated as in A were blotted with antibodies that specifically recognize c-Src when it is phosphorylated
on its autophosphorylation site (pSrcY416). C, cell extracts from GD251A and GD251TR cells plated for 30 min on dishes coated with mAb
TS2/16 to 1 integrin were immunoprecipitated with antibodies to p130Cas. Immunoprecipitates were blotted with antibody PY99 to phosphoty-
rosine (upper panel) and reblotted with mAb to p130Cas (lower panel). D, cells derived from p130Cas/ and p130Cas/ embryos were detached
from culture dishes and plated for 30 min on fibronectin-coated dishes in the presence or in the absence of 50 ng/ml EGF or kept in suspension (S).
Immunoprecipitated EGF receptor was immunoblotted with antibody PY99 to phosphotyrosine (upper left panel) or to EGF receptor (lower left
panel) or to p130Cas (right panel). The data reported here are representative of three distinct experiments.
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treatment. The use of two antibodies to phosphorylated tyro-
sine 1086 or 1173 shows also that these two residues are
phosphorylated after adhesion (second panel from top and sec-
ond from bottom), indicating that tyrosine 845 and 1068 are not
the unique sites phosphorylated in response to integrin-medi-
ated adhesion. Densitometric analysis of the Western blots
shows that tyrosine 1068 is strongly phosphorylated after ad-
hesion: the extent of phosphorylation was 70% of that found in
cells treated with 10 ng/ml EGF. Kinetic analysis of phospho-
rylated tyrosines shows that phosphorylation of 1068 and 1086
peaks at 15 min and is slightly reduced within 30 min of
adhesion. Tyrosine 1173 is also phosphorylated at 15 min, even
if at a lesser extent, and its phosphorylation is down-regulated
within 30 min. In addition, phosphorylation of all of these sites
was abolished in presence of tyrphostin AG1478, suggesting
that phosphorylation occurs via the EGF receptor kinase. It
would also be possible that selective inhibition of tyrosine phos-
phatases contributes to increased EGF receptor tyrosine phos-
phorylation on specific sites in response to adhesion. To inves-
tigate this possibility, cells were plated for 15 min on matrix
ligands to trigger EGF receptor phosphorylation, then the EGF
receptor kinase was “frozen” by treatment with tyrphostin
AG1478; phosphorylation was analyzed at 30 and 60 min of
adhesion. AG1478 treatment abolishes phosphorylation of ty-
rosine 1068 and 1173, indicating that the EGF receptor kinase
activity, rather than a decreased phosphatase activity, is re-
quired to maintain tyrosine phosphorylation of these two resi-
dues (data not shown). These data show that after integrin-de-
pendent cell-matrix adhesion, specific EGF receptor tyrosine
residues become phosphorylated and that they do not corre-
spond to all of the major sites previously shown to be phospho-
rylated in response to EGF.
Integrin-dependent Adhesion Increases the Amount of Cell
Surface-exposed EGF Receptor—The integrin-EGF receptor
complex can be immunoprecipitated from the cell surface either
with antibodies to integrin subunits or to EGF receptors (33).
When the EGF receptor is immunoprecipitated, the amount of
EGF receptor recovered from the surface of cells plated on v
ligand is higher than that obtained from cells plated on PL (Fig.
7A). In the presence of c-Src kinase inhibitor PP1, however, the
level of EGF receptor decreases to that observed in cells plated
on PL (Fig. 7A). Densitometric analysis show a 50% increase of
EGF receptor level in cells plated on integrin ligands (Fig. 7B).
These data suggest that integrin-mediated adhesion increases
the EGF receptor detectable on the cell surface. The results
obtained by immunoprecipitation were confirmed by immuno-
electron microscopy analysis. Gold particle counting increases
in cells plated on v ligand compared with cells plated on PL
and is reduced in the presence of c-Src inhibitor PP1 (Fig. 7B).
Therefore these data show that cell-matrix adhesion induces a
c-Src-dependent increase in the EGF receptor level on the cell
surface.
DISCUSSION
In this study we dissect the molecular mechanisms leading to
integrin-dependent tyrosine phosphorylation of EGF receptors,
which occurs upon cell-matrix adhesion. We show that: 1) after
adhesion, integrins and EGF receptors transiently associate in
a macromolecular complex, which contains the c-Src kinase
and the adaptor molecules p130Cas and Crk; 2) c-Src and EGF
receptor kinases are both required for association of integrins
and EGF receptors; 3) complex formation is required for EGF
receptor phosphorylation; 4) the 1 integrin cytoplasmic do-
main and the adaptor molecule p130Cas are additional ele-
ments required to trigger integrin-dependent EGF receptor
phosphorylation; 5) integrins induce a pattern of EGF receptor
phosphorylation distinct from that induced by EGF.
Formation of integrins and growth factor receptor macromo-
lecular complexes has been suggested by co-clustering and
immunofluorescence experiments (21, 31, 51) as well as by
direct coimmunoprecipitation (19, 22, 28, 33, 51, 52). While
most of these complexes were detected in response to growth
factor stimulation, we show here that in the absence of growth
factors, integrins dynamically associate with the EGF receptor
in response to cell/matrix interaction. The integrin-EGF recep-
tor macromolecular complex is specifically localized at the cell
membrane and is a dynamic structure that is detectable at 5
min of cell adhesion and rapidly down-regulated.
In addition to integrins and the EGF receptor, this complex
also includes molecules involved in signal transduction, such as
c-Src, p130Cas, and Crk. Our data show that c-Src is activated
after adhesion and phosphorylated on tyrosine residue 416 in
the activation loop, suggesting that c-Src is activated through
an autophosphorylation mechanism. The activated form of c-
Src is present in the integrin-EGF receptor complex, suggest-
ing a role for this kinase in complex assembly. This was con-
firmed by using a pharmacological inhibitor of Src kinase
activity and a kinase-defective construct, which both prevent
complex assembly. Inhibition of c-Src kinase activity blocks
association of integrins, EGF receptor, p130Cas, and c-Src,
demonstrating that c-Src catalytic activity is required to build
up the macromolecular complex. In contrast, when EGF recep-
tor kinase activity is blocked by the specific tyrphostin AG1478,
integrins are still able to associate with c-Src, even if at a
reduced extent, but they lose their ability to coimmunoprecipi-
tate EGF receptor and p130Cas. Therefore these data indicate
that EGF receptor tyrosine kinase activity is necessary for its
association with integrins but is not required for association
between integrins and c-Src. Taken together these data suggest
that after adhesion, a hierarchy of events takes place, leading
first to integrin-dependent c-Src activation and then to c-Src
kinase-dependent recruitment of p130Cas and EGF receptors
in the macromolecular complex.
p125Fak kinase, which is known to associate with p130Cas
and c-Src (10, 53–55), is not present in the integrin-EGF recep-
tor complex. This finding is consistent with our result that
p125Fak is not required for tyrosine phosphorylation of EGF
receptors in response to integrins, as shown using cells derived
from p125Fak knock-out mice or p125Fak dominant negative
mutants. Recently Sieg et al. (56) reported the ability of
p125Fak to associate in a complex with EGF receptors. The
lack of p125Fak coprecipitation in our experiments is likely to
be the result of the different experimental conditions used.
These authors detected this association in stable adherent cells
only in response to EGF, whereas our analysis was performed
in the absence of EGF on cells in the early phases of integrin-
mediated adhesion.
As discussed above c-Src catalytic activity is required for
integrin-EGF receptor macromolecular complex formation. In
addition c-Src catalytic activity is also critical for EGF receptor
phosphorylation, indicating that the macromolecular complex
is required to trigger EGF receptor phosphorylation. A central
TABLE I
EGF receptor phosphotyrosines identified by MALDI-TOF mass
spectrometry analysis after in-gel digestion
Tryptic peptides Expected massMH
Measured mass MH
S v
L837-K851 1,630.807 1,630.691 1,630.862
L837-K851 (P-Y845) 1,710.773 1,710.836
Y1045-K1075 3,398.617 3,398.329 3,398.572
Y1045-K1075 (P-Y1068) 3,478.583 3,478.242
G1137-K1155 2,236.031 2,236.033 2,236.107
G1137-K1155 (P-Y1148) 2,315.997
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role for c-Src in integrin signaling has been underlined by
several experiments (for review, see Ref. 57). Fibroblasts de-
rived from Src-deficient mice show delayed spreading on fi-
bronectin (58) or vitronectin (59), suggesting that c-Src modu-
lates integrin-dependent adhesion and spreading by regulating
the strength or dynamics of integrin/cytoskeleton interactions.
In addition, c-Src is involved in focal adhesion formation and
disassembly (60), and the triple mutant SYF(Src/, Yes/,
and Fyn/) cells are deficient in fibronectin-induced tyrosine
phosphorylation of focal adhesion protein (61). Kinase activity
of c-Src has also been shown to associate with v3 integrin in
osteoclasts and melanoma cells (62), indicating that integrins
and c-Src function in association. Consistent with our data,
c-Src has also been shown to be involved in integrin-dependent
RON phosphorylation (63).
In addition to c-Src kinase, the 1 integrin cytoplasmic do-
main as well as p130Cas protein are additional elements re-
quired for integrin-dependent EGF receptor phosphorylation.
The 1 integrin mutant lacking the cytoplasmic domain does
not trigger EGF receptor phosphorylation, indicating that the
cytoplasmic domain is required to induce this event. Interest-
ingly, integrin heterodimers in which the integrin 1 subunit
cytoplasmic domain is truncated still activate c-Src, thus sug-
gesting that either the  subunit or the extracellular part of the
molecule is required for this function. Previous reports have
indeed indicated a role for specific  subunits in Src family
kinase activation (5, 12). 1 integrins lacking the cytoplasmic
domain, however, show an impaired ability to phosphorylate
p130Cas. p130Cas adaptor protein is required for integrin-de-
pendent EGF receptor phosphorylation, as shown by using
fibroblasts derived from p130Cas/ mice. p130Cas phospho-
rylation and localization to focal adhesions has been shown to
be dependent on c-Src (47, 48). Our data show also that the
cytoplasmic domain of 1 integrin is required for integrin-de-
pendent p130Cas phosphorylation, suggesting that the 1 cy-
toplasmic domain is crucial for correct membrane targeting of
p130Cas and its assembly in the integrin-EGF receptor
complex.
As shown above, the integrin-EGF receptor macromolecular
complex is a dynamic structure that is rapidly down-regulated
from the cell surface. Integrin-dependent EGF receptor phos-
phorylation takes place at the same time as complex assembly,
but it is more persistent, remaining high within 30 min of
adhesion, even when the complex is disassembled. The basis of
this phenomenon is unclear at present. Interestingly, an EGF
receptor new activation mechanism has recently been shown,
which consists in ligand-independent rapid and extensive prop-
agation of receptor phosphorylation over the entire cell after
focal stimulation (64).
MALDI-TOF mass spectrometry analysis and the use of
phospho-specific antibodies led us to detect integrin-dependent
phosphorylation of four EGF receptor tyrosines, namely the
845, 1068, 1086 and 1173 residues. Interestingly, tyrosine 1148
is not phosphorylated in response to adhesion. This tyrosine
residue, however, is a major site that is phosphorylated in
response to EGF (49, 50), and we detected its phosphorylation
by both mass spectrometry and phospho-specific antibody
staining (Fig. 6). These data thus strongly indicate that inte-
grins induce a pattern of EGF receptor phosphorylation dis-
tinct from that induced by EGF. The fact that tyrosine 1148 is
not phosphorylated in response to adhesion reflects a distinct
mechanism of phosphorylation of EGF receptors in response to
adhesion rather than to EGF. This hypothesis is also supported
by the finding that c-Src activity is required for integrin-de-
FIG. 6. EGF receptor tyrosine 1068, 1086, and 1173 are phosphorylated by integrin-dependent adhesion. ECV304 cells were kept in
suspension (S) or plated for 15 and 30 min on dishes coated with mAb L230 to the v integrin subunit in the presence or absence of 10 ng/ml EGF
or 250 nM EGF receptor kinase inhibitor tyrphostin AG1478. Cell extracts were subjected to 6% SDS-PAGE and blotted with antibodies that
specifically recognize phosphorylated tyrosine 1068 (pY1068 EGFR), 1086 (pY1086 EGFR), 1173 (pY1173 EGFR) or 1148 (pY1148 EGFR). The
same blots were reblotted with antibodies to EGF receptor for normalization (bottom left panel). Densitometric analysis of each experiment is
shown on the right. The data reported here are representative of three distinct experiments.
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pendent EGF receptor phosphorylation but not for ligand-de-
pendent phosphorylation. The mechanisms responsible for the
lack of phosphorylation of tyrosine 1148 are unclear and could
be the result of either masking of this specific site within the
complex or the presence of an active site-specific phosphatase.
Tyrphostin AG1478 abolishes phosphorylation of 1068, 1086,
and 1173, indicating that EGF receptor kinase plays a primary
role in this phosphorylation. Phosphorylation of tyrosine resi-
dues depends on a balance between kinase and phosphatase
activity. When EGF receptor kinase was frozen with tyrphostin
AG1478 after phosphorylation has occurred (the addition of
tyrphostin at 15 min of adhesion), phosphorylation of tyrosine
1068 and 1173 was rapidly lost, indicating that increased EGF
receptor kinase activity rather than decreased phosphatase
activity controls the phosphorylation process. Nevertheless
EGF receptors are known to interact with tyrosine phospha-
tase SHIP2 (65), which has also been recently reported as a
p130Cas interactor (66). Therefore we cannot exclude that pro-
tein-tyrosine phosphatases that are present in the complex
could be somehow regulated in the integrin-dependent EGF
activation process.
c-Src kinase activity regulates EGF receptor phosphoryla-
tion either because it is required for the assembly of the inte-
grin-EGF receptor complex, which, in turn, allows EGF recep-
tor phosphorylation, or because it directly regulates the EGF
receptor kinase. Analysis of the phosphorylated EGF receptor
sites shows that tyrosine 845 is phosphorylated upon adhesion-
mediated receptor activation. Previous data showed that tyro-
sine 845 can be phosphorylated by c-Src in vitro (67) and in vivo
in cells overexpressing active c-Src kinase (68). Our data, show-
ing that c-Src is required for integrin-dependent EGF receptor
phosphorylation, suggest the possibility that tyrosine 845 can
be directly phosphorylated by c-Src.
Therefore we propose a model in which, after cell-matrix
adhesion, c-Src kinase is activated, associates in a complex
with integrins, p130Cas, and EGF receptors, leading to phos-
phorylation of EGF receptors at specific tyrosine residues, such
as 1068, 1086, and 1173, but not the 1148 site (Fig. 8).
Endocytosis of growth factor receptors is an important step in
growth factor activity, known to regulate downstream signaling
(69, 70). An interesting observation emerging from our data is
that in cells adherent to integrin ligands, the amount of EGF
receptor localized on the cell membrane is significantly
increased, suggesting that in the early phases of integrin-depend-
ent adhesion, EGF receptors are stabilized on the plasma mem-
brane. This event occurs in the earliest phases of cell adhesion,
indicating that the increased expression observed cannot be the
result of increased transcription. Additional experiments will
clarify whether this event might depend on reduced internaliza-
tion or increased recycling and whether it can play any role in
EGF receptor internalization process. Nevertheless this increase
is abolished when c-Src kinase is inhibited, a condition shown to
prevent complex formation and EGF receptor phosphorylation,
thus strongly suggesting that integrin-EGF receptor complex
formation triggers specific events responsible for increased EGF
receptor exposure on the cell surface.
Integrins have been shown to potentiate signaling pathways
in response to insulin, EGF, platelet-derived growth factor,
fibroblast growth factor, and vascular endothelial growth factor
(19–24, 28; for review, see Ref. 29). The ability of integrins to
transactivate EGF receptors, as reported in our work, can thus
represent a molecular mechanism at the basis of this phenom-
enon. Indeed integrin-dependent growth factor receptor activa-
tion is not restricted to the EGF receptor. It has been shown, in
fact, that cell/matrix interaction stimulates phosphorylation of
hepatocyte growth factor receptors (30, 32), platelet-derived
FIG. 7. Adhesion to v antibodies increases EGF receptor level
on the cell surface. A, ECV304 cells were plated for 5 min on dishes
coated with PL and postcoated with mAb L230 to the v integrin
subunit in the presence or absence of 5 M Src inhibitor PP1. mAb 8509
to EGF receptor was then added on the cells, which were incubated
further for 30 min at 4 °C before detergent extraction. Cells extracts
were immunoprecipitated by the addition of protein A-Sepharose (IP
anti EGFR), and the immunoprecipitates were blotted with antibodies
to EGF receptor (EGFR), p130Cas, and c-Src. B, densitometric analysis
of the experiment reported in A; EGF receptor levels are reported in
arbitrary units. C, ECV304 cells treated in the same conditions as in A
were fixed and frozen in liquid nitrogen. Ultrathin cryosections were
immunostained with mouse monoclonal anti hEGFR followed by a
rabbit anti-mouse bridging antibody (DAKO) and 15-nm protein A-gold.
Sections were examined with a Zeiss EM 902 electron microscope. The
data reported here are representative of three distinct experiments.
FIG. 8. Model of integrin-dependent EGF receptor phosphoryl-
ation. In response to cell-matrix adhesion, c-Src kinase is phosphoryl-
ated on tyrosine 416 (PY416) and associates in a complex with inte-
grins, p130Cas, Crk, and EGF receptor. As a consequence of cell
adhesion, EGF receptor is phosphorylated on tyrosine 845, 1068, 1086,
and 1173, but not on tyrosine 1148.
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growth factor  receptors (31), and RON kinase (63), suggesting
that activation of growth factor receptors in the absence of their
specific ligands can be a broadly used mechanism in adhesion-
mediated signaling.
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